FMO5 and diabetes mellitus: Both genetic and observational studies have reported that higher levels of ceramides were associated with an increased risk of CVD events and diabetes (Diaz et al., 2021; Fretts et al., 2021; Tabassum et al., 2019), potentially through activation of NADPH oxidase and disruption of mitochondrial function (Choi et al., 2021).